BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

597 related articles for article (PubMed ID: 19402821)

  • 21. The proline-rich Akt substrate of 40 kDa (PRAS40) is a physiological substrate of mammalian target of rapamycin complex 1.
    Oshiro N; Takahashi R; Yoshino K; Tanimura K; Nakashima A; Eguchi S; Miyamoto T; Hara K; Takehana K; Avruch J; Kikkawa U; Yonezawa K
    J Biol Chem; 2007 Jul; 282(28):20329-39. PubMed ID: 17517883
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prolactin activates mammalian target-of-rapamycin through phosphatidylinositol 3-kinase and stimulates phosphorylation of p70S6K and 4E-binding protein-1 in lymphoma cells.
    Bishop JD; Nien WL; Dauphinee SM; Too CK
    J Endocrinol; 2006 Aug; 190(2):307-12. PubMed ID: 16899564
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of PI3K-Akt-mTOR signaling in glioblastoma by mTORC1/2 inhibitors.
    Fan QW; Weiss WA
    Methods Mol Biol; 2012; 821():349-59. PubMed ID: 22125077
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PRR5, a novel component of mTOR complex 2, regulates platelet-derived growth factor receptor beta expression and signaling.
    Woo SY; Kim DH; Jun CB; Kim YM; Haar EV; Lee SI; Hegg JW; Bandhakavi S; Griffin TJ; Kim DH
    J Biol Chem; 2007 Aug; 282(35):25604-12. PubMed ID: 17599906
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PRAS40 regulates mTORC1 kinase activity by functioning as a direct inhibitor of substrate binding.
    Wang L; Harris TE; Roth RA; Lawrence JC
    J Biol Chem; 2007 Jul; 282(27):20036-44. PubMed ID: 17510057
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Both mTORC1 and mTORC2 are involved in the regulation of cell adhesion.
    Chen L; Xu B; Liu L; Liu C; Luo Y; Chen X; Barzegar M; Chung J; Huang S
    Oncotarget; 2015 Mar; 6(9):7136-50. PubMed ID: 25762619
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of rictor as a novel substrate of Polo-like kinase 1.
    Shao T; Liu X
    Cell Cycle; 2015; 14(5):755-60. PubMed ID: 25714006
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of insulin signaling and adipogenesis by rapamycin: effect on phosphorylation of p70 S6 kinase vs eIF4E-BP1.
    El-Chaâr D; Gagnon A; Sorisky A
    Int J Obes Relat Metab Disord; 2004 Feb; 28(2):191-8. PubMed ID: 14970836
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Simultaneous inhibition of mTORC1 and mTORC2 by mTOR kinase inhibitor AZD8055 induces autophagy and cell death in cancer cells.
    Sini P; James D; Chresta C; Guichard S
    Autophagy; 2010 May; 6(4):553-4. PubMed ID: 20364113
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Significance of 4E-binding protein 1 as a therapeutic target for invasive urothelial carcinoma of the bladder.
    Nishikawa M; Miyake H; Behnsawy HM; Fujisawa M
    Urol Oncol; 2015 Apr; 33(4):166.e9-15. PubMed ID: 25618298
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Simultaneous inhibition of mTOR-containing complex 1 (mTORC1) and MNK induces apoptosis of cutaneous T-cell lymphoma (CTCL) cells.
    Marzec M; Liu X; Wysocka M; Rook AH; Odum N; Wasik MA
    PLoS One; 2011; 6(9):e24849. PubMed ID: 21949767
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Curcumin disrupts the Mammalian target of rapamycin-raptor complex.
    Beevers CS; Chen L; Liu L; Luo Y; Webster NJ; Huang S
    Cancer Res; 2009 Feb; 69(3):1000-8. PubMed ID: 19176385
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dramatic suppression of colorectal cancer cell growth by the dual mTORC1 and mTORC2 inhibitor AZD-2014.
    Huo HZ; Zhou ZY; Wang B; Qin J; Liu WY; Gu Y
    Biochem Biophys Res Commun; 2014 Jan; 443(2):406-12. PubMed ID: 24309100
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Activation of the p70 S6 kinase and phosphorylation of the 4E-BP1 repressor of mRNA translation by type I interferons.
    Lekmine F; Uddin S; Sassano A; Parmar S; Brachmann SM; Majchrzak B; Sonenberg N; Hay N; Fish EN; Platanias LC
    J Biol Chem; 2003 Jul; 278(30):27772-80. PubMed ID: 12759354
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The TSC1-TSC2 complex is required for proper activation of mTOR complex 2.
    Huang J; Dibble CC; Matsuzaki M; Manning BD
    Mol Cell Biol; 2008 Jun; 28(12):4104-15. PubMed ID: 18411301
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevention of Akt phosphorylation is a key to targeting cancer stem-like cells by mTOR inhibition.
    Matsubara S; Tsukasa K; Kuwahata T; Takao S
    Hum Cell; 2020 Oct; 33(4):1197-1203. PubMed ID: 32851605
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hydrogen peroxide impairs insulin-stimulated assembly of mTORC1.
    Zhang L; Kimball SR; Jefferson LS; Shenberger JS
    Free Radic Biol Med; 2009 Jun; 46(11):1500-9. PubMed ID: 19281842
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Platelet-derived growth factor-induced Akt phosphorylation requires mTOR/Rictor and phospholipase C-γ1, whereas S6 phosphorylation depends on mTOR/Raptor and phospholipase D.
    Razmara M; Heldin CH; Lennartsson J
    Cell Commun Signal; 2013 Jan; 11(1):3. PubMed ID: 23311350
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Akt is efficiently activated by PIF-pocket- and PtdIns(3,4,5)P3-dependent mechanisms leading to resistance to PDK1 inhibitors.
    Najafov A; Shpiro N; Alessi DR
    Biochem J; 2012 Dec; 448(2):285-95. PubMed ID: 23030823
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Autoregulation of the mechanistic target of rapamycin (mTOR) complex 2 integrity is controlled by an ATP-dependent mechanism.
    Chen CH; Kiyan V; Zhylkibayev AA; Kazyken D; Bulgakova O; Page KE; Bersimbaev RI; Spooner E; Sarbassov DD
    J Biol Chem; 2013 Sep; 288(38):27019-27030. PubMed ID: 23928304
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.